This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Merus 과거 순이익 실적
과거 기준 점검 0/6
Merus 의 수입은 연평균 -34.9%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 5.9%의 비율로 증가해 왔습니다.
핵심 정보
-34.86%
순이익 성장률
-16.27%
주당순이익(EPS) 성장률
| Biotechs 산업 성장률 | 17.04% |
| 매출 성장률 | 5.86% |
| 자기자본이익률 | -49.18% |
| 순이익률 | -673.31% |
| 최근 순이익 업데이트 | 30 Sep 2025 |
최근 과거 실적 업데이트
Recent updates
Seeking Alpha • Sep 29
Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue
Summary Genmab acquires Merus for $8bn, gaining petosemtamab, a promising oncology asset, to diversify and strengthen its late-stage pipeline. Petosemtamab shows strong Phase 2 results in HNSCC, outperforming current standards and potentially offering multi-billion dollar revenue opportunities for GMAB. Despite robust financials and pipeline growth, GMAB faces risk from Darzalex's 2029 patent expiry, swapping revenue certainty for future potential. With MRUS shares near the buyout price and GMAB's stock up YTD, I recommend watching GMAB for pipeline progress before considering a buy. Read the full article on Seeking AlphaSeeking Alpha • Jan 20
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Summary Bizengri’s recent approval gives MRUS the first approved therapy for NRG1+ cancers, which, I think, will be a valuable niche. Petosemtamab’s recent Phase 2 data for HNSCC suggests it could also have blockbuster potential as long as its Phase 3 trials are successful as well. I also like MRUS’s recent partnership with BHVN as it gives it optionality with new ADC programs that could have oncology applications. In my view, MRUS's 2.4-year runway seems healthy, particularly because sales are likely going to ramp up in the next few years with Bizengri. Therefore, I feel MRUS is now a “Buy” after the recent 34.6% pullback from its highs. It has a great pipeline and aggregate TAM. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Summary Merus is nearing a major milestone with zenocutuzumab's potential FDA approval for NRG1+ NSCLC/PDAC, with a PDUFA date of February 4, 2025. Petosemtamab, targeting 1st and 2nd-line HNSCC, shows promise with updated data to be presented at ESMO Asia Congress in December 2024. Financially stable with $782.9 million in cash, Merus has strategic partnerships with Gilead, Eli Lilly, Incyte, and Ono Pharmaceutical, funding operations into 2028. The global head and neck cancer market is expected to reach $8.1 billion by 2031. Read the full article on Seeking AlphaSeeking Alpha • Aug 14
Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks
Summary Merus is a clinical-stage biotech focusing on bispecific and trispecific antibody therapies for various cancers using its Multiclonics platforms. MRUS collaborates with GILD and LLY, leveraging its Multiclonics platforms to develop innovative bispecific and trispecific antibodies. MRUS's pipeline includes promising product candidates like MCLA-158 and MCLA-128, showing positive results in challenging cancer types. Despite strong potential, MRUS’s cash burn and expensive valuation raise concerns about future shareholder dilution. Overall, I'm neutral on MRUS, but I think it's a worthwhile addition to the watchlist in case the stock declines significantly. Read the full article on Seeking AlphaSeeking Alpha • May 24
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
Summary Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear. The company's bispecific antibody, petosemtamab, showed promising results in a phase 2 study for head and neck squamous cell carcinoma. Merus' other bispecific antibody, zenocutuzumab, has a high chance of approval for NRG1-positive NSCLC and pancreatic cancer, with a decision expected later in 2024. Read the full article on Seeking AlphaSeeking Alpha • Mar 01
Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Summary Merus N.V. results from the phase 1/2 eNRGy trial, using zenocutuzumab for the treatment of patients with NRG1+ PDAC and NSCLC, are expected in the 1st half of 2024. Should results from the phase 1/2 eNRGy trial turn out to be positive, then Merus will be able to file BLA of zenocutuzumab for the treatment of patients NRG1+cancers. Petosemtamab is another clinical candidate being advanced in the pipeline for the treatment of both 1st-line and 2nd-line HNSCC; Data for each program targeting such populations is expected in 2024. Merus had $411.7 million in cash as of December 31st of 2023; Enough to fund its operations into 2027. Read the full article on Seeking AlphaSeeking Alpha • Jan 23
Merus Stock: Rally Seems Overdone
Summary Merus N.V. shares have remained strong despite negative safety news about its MCLA-129 program, as attention shifts to promising candidates petosemtamab and zenocutuzumab. Petosemtamab shows solid overall response rates for head and neck cancer, while zenocutuzumab is expected to file for BLA in mid-2024 for NGR1+ cancers. Merus has a strong balance sheet and multiple collaborations, with analyst firms optimistic about its prospects and a median price target objective of $46 a share. An analysis around Merus N.V. follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 08
Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Merus press release (NASDAQ:MRUS): Q2 GAAP EPS of -$0.13 beats by $0.49. Revenue of $12.68M (+2.4% Y/Y) beats by $2.23M.Seeking Alpha • Aug 02
Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
The shares of Dutch biotech Merus N.V. (NASDAQ:MRUS) added ~8% on Tuesday after Stifel initiated its coverage on the stock with a Buy recommendation as the analysts weighed in on the potential of thee of the company’s bispecific antibody candidates. Bispecific antibodies contain dual specificity in their binding arms and bind to two adjacent epitopes on a single target antigen, thereby raising the strength of the link. The analysts led by Bradley Canino point to near-term partnership potential of Merus’ (MRUS) solid tumor candidates Zenocutuzumab (MCLA-128) and MCLA-129 which is also undergoing studies for advanced non-small cell lung cancer. Despite a potentially weak Phase 1 data readout expected in 2H 2022 for the third asset MCLA-129 in head and neck cancer, the analysts cite the downside protection from Zenocutuzumab and MCLA-129. The two candidates command $400M and $525M peak sales potential in Stifel’s model, respectively compared to $200M for MCLA-129. The price target of $38 per share implying ~54% upside to the Merus’ (MRUS) Monday’s close, stands ~10% lower than the stock’s current average target on Wall Street.Seeking Alpha • Jun 30
Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Shares have risen by 40% since my 2020 ROTY update, but have lost a third of their value in 2022. I provide a recap of our thesis on this promising platform technology play in the oncology space. Data for Zeno in NRG1+ cancers at ASCO impressed with consistent ORR and clinical benefit (supportive of likely tumor agnostic label). Peto (EGFR LGR5) and c-MET drug candidates provide higher upside potential and more favorable risk/reward with data updates 2H 22. MRUS is a Buy. Key risks include disappointing data, high level of competition in EGFR and unfavorable partnership terms for potential collaborations (particularly commercial for Zeno). This article was originally published for ROTY subscribers on May 2nd, but has been updated where necessary. Shares of Merus (MRUS) have risen by 40% since my June 2020 ROTY update and sport a 35% gain over the past 5 years. On the other hand, they've shed a third of their value since the start of 2022 (taking a significant hit along with the overall biotech sector). In ROTY's model account, I purchased a 3% portfolio weighting in late April and added to our position multiple times after oral presentation for Zeno (HER2 x HER3 bispecific antibody) in NRG1 fusion cancers at ASCO on June 5th proved encouraging. Let's move on to my update on this intriguing platform technology play and why it potentially has the kind of clinical momentum and asymmetric risk/reward profile that would allow me to keep holding patiently. Chart Finviz Figure 1: MRUS weekly chart When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, we can see shares rise above $30 in early 2021 after the license agreement was inked with Loxo Oncology/Eli Lilly (LLY). From there, shares again rebounded in October after promising responses were reported for Peto/MCLA-158 in HNSCC (head and neck squamous cell carcinoma) at the AACR-NCI-EORTC conference. Currently, shares are trying to regain the 20-day moving average on the weekly chart and have rebounded nicely post ASCO presentation of Zeno data. My initial take is that investors interested in the name would do well to purchase a pilot position presently and add more exposure on dips ahead of Peto readout later this year. Overview In my 2020 update, I touched on the following keys to our bullish thesis: I stated that the company's mission is to pursue unique bispecific and trispecific cancer candidates based on well characterized immunoglobulin format (very easy to manufacture, low immunogenicity risk, improved half-life). I also pointed out that Merus' lead candidates are novel (not "me too" treatments). Corporate Slides Figure 2: Pipeline MCLA-128 ((ZENO)) was thought to be the first HER3 targeting agent that's proven effective. Zeno uniquely blocks NRG1 heregulin interaction (these cancers typically don't have any other cancer driver mutations so they are truly driven by NRG1 gene fusion product and thus this particular MOA directly blocks this function). Early data in patients whose cancers harbored NRG1 fusions was promising, including partial responses in multiple pancreatic cancer patients as well as a NSCLC (non small cell lung cancer) patient. These subjects were heavily pretreated, including the latter with 6 prior lines of therapy. Importantly, the drug was well tolerated with a strong safety profile. Corporate Slides Figure 3: Zeno safety profile, mainly Grade 1 to 2 adverse events As for market opportunity, I pointed to company estimates of these fusions occurring in 0.3% to 3% of NSCLC, 0.5 to 1.5% of pancreatic cancer and less than 1% in other solid tumor types. AACR post on prevalence indicated market opportunity could be smaller (identified NRG1 fusions in approximately 0.2% of over 20,000 patients with diverse tumor types including 0.3% in patients with lung cancer). Following in the steps of precision oncology pioneers such as Loxo, management believed an efficient path to market exists via single arm enrichment study. As for MCLA-158, I noted that this first-in-class bispecific antibody is targeting LGLR5 (leucine-rich repeat-containing G protein-coupled receptor 5) and EGFR. For a frame of reference, I cited cetuximab (Erbitux) which at its peak achieved global sales of close to $2 billion despite a safety profile that left much to be desired (the rash comes to mind as one AE leading to dose reduction or treatment discontinuation). Corporate Slides Figure 4: Peto's innovative mechanism of action would appear to offer the best of both worlds, selectivity & efficacy, in preclinical models As for leadership, I noted that prior CEO and President Dr. Ton Logtenberg was stepping down with Dr. Sven Lundberg to succeed him. New CEO Lundberg appeared to have some relevant experience, including serving prior as Chief Scientific Officer at CRISPR Therapeutics and as Head of Translational Medicine at Alexion Pharmaceuticals. Thus, he seemed to be a good fit to take the company into its next stage of value creation. Two appointments to Board of Directors caught my interest, Dr. Anand Mehra (General Partner at Soffinova Investments) and Paolo Pucci (former CEO of ArQule, where he led an impressive turnaround that culminated with the $2.7 billion buyout by Merck). I also highlighted Dr Victor Sandor on the board, who served prior as Chief Medical Officer at Array BioPharma, which was acquired by Pfizer for $11.4 billion. Let's move onto my notes from Needham Virtual Conference webcast. Needham Notes CEO Bill Lundberg starts by highlighting the common light chain technology utilized in Merus' Biclonics and Triclonics, which allows them to produce monoclonals out of a single cell. For Zeno, they met with the FDA at the end of last year, aligning on NRG1 fusion cancers being a population that could receive a drug approval and that the company's ongoing clinical program could support such a filing (if efficacy and number of patients is sufficient). Lundberg expects they have aligned with the FDA and will have sufficient enrollment and patient follow up to support BLA filing. This is a competitive space, but there have been 5 prior approvals for tumor agnostic setting for solid tumors (among them, response rates ranged from 29% to 75% with durability of 5 months all the way to 1 year). If data is consistent with that range, they have potential for BLA filing. They did discuss specific, granular numbers with the FDA but have chosen not to share them for competitive reasons. As for Zeno's commercial opportunity (challenge of finding and identifying these patients), they have been successful enrolling 100+ patients in study which for uncommon tumor type is promising. The general trend toward personalized medicine should provide a tailwind as well (molecular panels already include NRG1). If patients have RAS wild type mutation, that is a smaller subtype in which NRG1 fusions almost exclusively occur. More recently, they have been able to enroll virtually every patient on the eNRGy trial instead of Early Access Program (as Covid has let up some). One key caveat is that Lundberg is "hopeful" the data package would be supportive of regulatory filing, but this sounds far from certain. As for MCLA-158 (Peto), Lundberg notes that LGR5 is not typically expressed after birth (small subsets of cancer stem cells express the target as do certain cancer subtypes including colorectal, head & neck, gastric esophageal). These 3 cohorts are what they're interested in testing the drug in. In fall of last year, they presented early data on an initial cohort of previously treated HNSCC patients. 7 of 10 patients reached their first tumor evaluation, and all 7 had tumor shrinkage with 3 partial responses (1 PR deepened to complete response after data cutoff date). Keep in mind these patients with 2 prior lines of therapy are treated typically with a platinum and a biologic, with few good options after that (historical response rate for cetuximab is just 13%). Corporate Slides Figure 5: Peto's early clinical activity in HNSCC As for other tumor types, Lundberg says they have another cohort of gastric esophageal that they will present at the same conference as updated HNSCC results. Protocol allows for enrolling up to 40 patients for HNSCC. The caveat is again it's early in the study and we need to see strong signal in higher number of patients. Moving onto MCLA-129 (EGFR c-MET bispecific antibody), they started developing it several years ago when it became clear that one major mechanism of resistance to EGFR targeting drugs was activation of MET pathway. The drug entered clinic in Q2 last year in phase 1/2 dose escalation study. AACR poster demonstrated preclinical data, showing the antibody blocks mechanism of action for EGFR and c-MET. The drug also induces ADCC and ADCP which rely on host immune system to kill cancer cells. MCLA-129 also blocks the growth of cancer in mouse model with EGFR exon20 mutation. Corporate Slides Figure 6: MCLA-129 supportive preclinical data As for competition and differentiation, Johnson & Johnson's (JNJ) Rybrevant is already on the market and also binds to EGFR/c-MET. MCLA-129 appears to have similar affinity to both targets, whereas Rybrevant binds tighter to c-MET (more similar affinities gives wider therapeutic window generally speaking). 129 is also fully ADCC-enhanced, Rybrevant may only be half-ADCC enhanced. 129 is produced from a single cell (advantages of monoclonal antibody production), whereas Rybrevant must be produced through making two monospecific antibodies then mixing them together in a costly and time-consuming process. It's too early to state whether MCLA-129 has an advantage in safety or efficacy (or merely similar in base case scenario). The goal is to find the recommended phase 2 dose, evaluate early evidence of efficacy in multiple cohorts to decide where they should invest in (early evidence suggests pursuit of additional indications outside of NSCLC as well). Moving onto MCLA-145 (PD-L1 x CD137), expectations are low here considering that in January partner Incyte decided to opt out continued development. Early data was presented in December where they demonstrated 25mg range is the right range. They also believe they are not fully blocking PD-L1/PD1 access, so the drug could work better with full blockade (combine with PD-1 drug). Their trispecific TriClonics platform provides same technical advantages (being able to produce out of a single cell). Third binding domain adds complexity and could have technical advantages for a number of indications (active research here, but keeping new molecules under wraps it would seem). As for the balance sheet, they reported $430 million in cash at end of 2021 which will take them beyond 2024. Lundberg hints that partnerships could be appropriate for certain assets (which makes me think he's talking about c-MET) in being realistic about what late-stage studies and commercialization they can approve on their own. Other Information For Q1, the cash balance was $384M (down from $430.8M at December 31st). Net loss rose to $18.9M, while R&D rose by $6.2M to $27M. G&A rose by $2.4M to $11.75M. Management is guiding for operational runway beyond 2024. Key milestones remain unchanged, including data updates for Peto (Lgr5 x EGFR) and MCLA-129 (EGFR x c-MET) in the second half of the year. Here are a couple nuggets from May 24th Wainwright webcast: Peto (EGFR x LGR5) they saw 3 clinical responses out of 7 evaluable HNSCC patients in early data, with all 7 showing signs of tumor shrinkage. They will be providing update on HNSCC cohort 2H 22 (interesting that they don't mention gastric this time). Platform allows them to develop large inventory of diverse panel of common light chain antibodies against numerous targets. They can evaluate thousands of multi-specific antibodies in parallel using robotics and automation, then evaluate them in screening to identify best candidates for clinical application (does not guarantee success but gives them higher probability of success). On May 26th, the company announced publication of Zeno data in phase 1/2 eNRGY trial via abstract on ASCO website. Of 73 evaluable patients, a very respectable 34% overall response rate was observed with median duration of response ((DOR)) of 9.1 months. 35% response rate in NSCLC and 39% ORR in pancreatic cancer appears approvable to my eyes (well within FDA guidance). Breast cancer 2/4 responders and cholangiocarcinoma 1/3 responders also looks good, a caveat is the low number of patients. Corporate Slides Figure 7: Zeno shows broad activity across multiple NRG1+ tumor types Merus is well ahead of competitor Elevation Oncology, who enrolled just 15 patients in its CRESTONE study so far though the 33% response rate for seribantumab lines up well with Zeno (mainly NSCLC patients, only 1 pancreatic). ASCO oral update (see slides) contained little in the way of surprises, with 34% overall response rate in 79 evaluable patients. Pancreatic cancer (PDAC) response rate increased from 39% in prior abstract to 42%, which is good to see. Importantly, as noted prior, the company remains 2+ years ahead of competition in NRG1+ tumors.매출 및 비용 세부 내역
매출 및 비용 세부 내역
Merus가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 30 Sep 25 | 57 | -381 | 99 | 293 |
| 30 Jun 25 | 56 | -386 | 91 | 203 |
| 31 Mar 25 | 55 | -277 | 89 | 203 |
| 31 Dec 24 | 36 | -215 | 83 | 203 |
| 30 Sep 24 | 36 | -245 | 75 | 175 |
| 30 Jun 24 | 35 | -168 | 67 | 129 |
| 31 Mar 24 | 38 | -150 | 61 | 129 |
| 31 Dec 23 | 44 | -155 | 60 | 129 |
| 30 Sep 23 | 46 | -177 | 59 | 91 |
| 30 Jun 23 | 41 | -178 | 59 | 0 |
| 31 Mar 23 | 43 | -152 | 56 | 0 |
| 31 Dec 22 | 42 | -131 | 52 | 139 |
| 30 Sep 22 | 46 | -64 | 48 | 0 |
| 30 Jun 22 | 53 | -54 | 45 | 0 |
| 31 Mar 22 | 52 | -76 | 43 | 0 |
| 31 Dec 21 | 49 | -67 | 41 | 0 |
| 30 Sep 21 | 43 | -80 | 40 | 0 |
| 30 Jun 21 | 38 | -89 | 39 | 0 |
| 31 Mar 21 | 32 | -79 | 36 | 0 |
| 31 Dec 20 | 30 | -86 | 36 | 0 |
| 30 Sep 20 | 29 | -83 | 35 | 0 |
| 30 Jun 20 | 28 | -69 | 34 | 0 |
| 31 Mar 20 | 29 | -65 | 34 | 0 |
| 31 Dec 19 | 31 | -55 | 32 | 0 |
| 30 Sep 19 | 37 | -32 | 43 | 0 |
| 30 Jun 19 | 35 | -34 | 38 | 0 |
| 31 Mar 19 | 36 | -26 | 33 | 0 |
| 31 Dec 18 | 38 | -28 | 29 | 0 |
| 30 Sep 18 | 34 | -41 | 13 | 0 |
| 30 Jun 18 | 33 | -45 | 14 | 0 |
| 31 Mar 18 | 34 | -66 | 16 | 0 |
| 31 Dec 17 | 26 | -78 | 17 | 0 |
| 30 Sep 17 | 18 | -100 | 18 | 0 |
| 30 Jun 17 | 12 | -87 | 13 | 0 |
| 31 Mar 17 | 6 | -66 | 9 | 0 |
| 31 Dec 16 | 3 | -50 | 5 | 0 |
| 30 Sep 16 | 4 | -25 | 2 | 0 |
| 30 Jun 16 | 3 | -26 | 2 | 0 |
| 31 Mar 16 | 3 | -27 | 1 | 0 |
| 31 Dec 15 | 2 | -25 | 1 | 0 |
| 30 Sep 15 | 2 | -25 | 1 | 0 |
| 30 Jun 15 | 2 | -23 | -1 | 0 |
| 31 Mar 15 | 1 | -20 | 0 | 0 |
양질의 수익: MRUS 은(는) 현재 수익성이 없습니다.
이익 마진 증가: MRUS는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: MRUS은 수익성이 없으며 지난 5년 동안 손실이 연평균 34.9% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 MRUS의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: MRUS은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: MRUS는 현재 수익성이 없으므로 자본 수익률이 음수(-49.18%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2025/12/31 15:32 |
| 종가 | 2025/12/29 00:00 |
| 수익 | 2025/09/30 |
| 연간 수익 | 2024/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Merus N.V.는 16명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Etzer Darout | Barclays |
| Yigal Nochomovitz | Citigroup Inc |
| Richard J. Law | Goldman Sachs |